Akari Therapeutics PLC (NASDAQ:AKTX) dropped 3.1% during trading on Wednesday . The stock traded as low as $1.86 and last traded at $1.90, approximately 183,442 shares traded hands during mid-day trading. An increase of 71% from the average daily volume of 107,011 shares. The stock had previously closed at $1.96.
Separately, Zacks Investment Research raised shares of Akari Therapeutics from a “sell” rating to a “hold” rating and set a $2.00 price target on the stock in a research report on Thursday, November 7th.
The stock has a market capitalization of $32.67 million, a PE ratio of -11.18 and a beta of -2.81. The business’s 50-day moving average is $1.84 and its two-hundred day moving average is $1.96.
Akari Therapeutics (NASDAQ:AKTX) last released its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.02). Equities analysts expect that Akari Therapeutics PLC will post -1 EPS for the current fiscal year.
An institutional investor recently raised its position in Akari Therapeutics stock. Virtu Financial LLC increased its stake in shares of Akari Therapeutics PLC (NASDAQ:AKTX) by 185.8% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 31,124 shares of the biopharmaceutical company’s stock after acquiring an additional 20,232 shares during the period. Virtu Financial LLC owned approximately 0.20% of Akari Therapeutics worth $53,000 at the end of the most recent reporting period. Institutional investors own 13.54% of the company’s stock.
About Akari Therapeutics (NASDAQ:AKTX)
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome.
Recommended Story: How prevalent are 12b-1 fees?
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.